Eqis Capital Management Inc. Buys New Stake in PAREXEL International Corporation (NASDAQ:PRXL)

Eqis Capital Management Inc. bought a new position in shares of PAREXEL International Corporation (NASDAQ:PRXL) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 3,969 shares of the medical research company’s stock, valued at approximately $345,000.

A number of other institutional investors have also recently made changes to their positions in PRXL. Public Employees Retirement System of Ohio boosted its position in shares of PAREXEL International Corporation by 4.5% in the first quarter. Public Employees Retirement System of Ohio now owns 1,713 shares of the medical research company’s stock worth $108,000 after buying an additional 73 shares during the period. Meadow Creek Investment Management LLC boosted its position in shares of PAREXEL International Corporation by 7.1% in the first quarter. Meadow Creek Investment Management LLC now owns 1,980 shares of the medical research company’s stock worth $125,000 after buying an additional 132 shares during the period. Baird Financial Group Inc. boosted its position in shares of PAREXEL International Corporation by 2.3% in the first quarter. Baird Financial Group Inc. now owns 5,812 shares of the medical research company’s stock worth $367,000 after buying an additional 133 shares during the period. Isthmus Partners LLC boosted its position in shares of PAREXEL International Corporation by 1.3% in the first quarter. Isthmus Partners LLC now owns 11,516 shares of the medical research company’s stock worth $727,000 after buying an additional 145 shares during the period. Finally, Capstone Asset Management Co. boosted its position in shares of PAREXEL International Corporation by 3.8% in the first quarter. Capstone Asset Management Co. now owns 4,409 shares of the medical research company’s stock worth $278,000 after buying an additional 160 shares during the period. Institutional investors own 91.58% of the company’s stock.

PAREXEL International Corporation (NASDAQ PRXL) traded up 0.02% during mid-day trading on Friday, hitting $87.66. The company had a trading volume of 721,498 shares. PAREXEL International Corporation has a 52-week low of $51.16 and a 52-week high of $87.86. The stock’s 50 day moving average price is $87.43 and its 200 day moving average price is $74.60. The firm has a market cap of $4.45 billion, a P/E ratio of 38.53 and a beta of 0.79.

TRADEMARK VIOLATION NOTICE: “Eqis Capital Management Inc. Buys New Stake in PAREXEL International Corporation (NASDAQ:PRXL)” was posted by BNB Daily and is the property of of BNB Daily. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.baseball-news-blog.com/2017/08/19/eqis-capital-management-inc-invests-345000-in-parexel-international-corporation-nasdaqprxl-updated-updated-updated.html.

A number of equities research analysts have issued reports on the company. Zacks Investment Research lowered PAREXEL International Corporation from a “buy” rating to a “hold” rating in a research report on Thursday. Barclays PLC lowered PAREXEL International Corporation from an “overweighr” rating to an “equal weight” rating and set a $87.00 price target on the stock. in a research report on Tuesday, June 20th. Credit Suisse Group reaffirmed a “neutral” rating and issued a $83.00 price target (up previously from $65.00) on shares of PAREXEL International Corporation in a research report on Tuesday, June 6th. Raymond James Financial, Inc. raised PAREXEL International Corporation from an “underperform” rating to a “mkt perform” rating in a research report on Tuesday, June 20th. Finally, Goldman Sachs Group, Inc. (The) raised PAREXEL International Corporation from a “sell” rating to a “neutral” rating and raised their target price for the stock from $63.00 to $77.00 in a research report on Tuesday, May 23rd. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and four have issued a buy rating to the company. PAREXEL International Corporation has a consensus rating of “Hold” and an average price target of $75.93.

About PAREXEL International Corporation

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Institutional Ownership by Quarter for PAREXEL International Corporation (NASDAQ:PRXL)

Receive News & Ratings for PAREXEL International Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply